According to DelveInsight, the Hypertriglyceridemia pipeline features 18+ key pharmaceutical companies actively developing over 20 therapeutic candidates targeting this condition.
Overview of Hypertriglyceridemia
Hypertriglyceridemia refers to a metabolic disorder characterized by elevated triglyceride levels in the bloodstream, which significantly increases the risk of cardiovascular diseases (CVD) and acute pancreatitis. The condition is often associated with uncontrolled diabetes, obesity, sedentary lifestyles, and genetic predispositions.
Typically, hypertriglyceridemia remains asymptomatic until triglyceride concentrations exceed 1,000–2,000 mg/dL, at which point serious complications such as pancreatitis and metabolic disturbances may develop.
Management strategies primarily emphasize lifestyle modifications—including dietary changes, weight management, and regular physical activity—and may be complemented by pharmacological interventions such as statins, fibrates, or omega-3 fatty acids when necessary. In addition, addressing underlying medical conditions is crucial to achieving optimal lipid control and minimizing cardiovascular risk.
Request for a detailed insights report on Hypertriglyceridemia pipeline insights
DelveInsight’s “Hypertriglyceridemia Pipeline Insight 2025” report offers an in-depth evaluation of the current clinical development landscape and emerging growth opportunities within the Hypertriglyceridemia therapeutics market.
Key Takeaways from the Hypertriglyceridemia Pipeline Report
-
DelveInsight’s Hypertriglyceridemia Pipeline Report highlights a dynamic and competitive landscape, featuring over 18 active companies engaged in the development of more than 20 investigational therapies for the treatment of Hypertriglyceridemia.
-
In December 2024, the FDA approved Tryngolza (olezarsen) as the first-ever therapy for familial chylomicronemia syndrome (FCS)—a rare and severe subtype of hypertriglyceridemia. Additionally, Arrowhead Pharmaceuticals’ plozasiran had its New Drug Application (NDA) accepted by the FDA in January 2025, with a PDUFA decision date scheduled for November 18, 2025.
-
Leading companies such as NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer Biologics, Ionis Pharmaceuticals, Inc., GeneCradle, MediciNova, and Regeneron Pharmaceuticals are actively working to advance novel therapeutic candidates aimed at enhancing the treatment landscape for hypertriglyceridemia.
-
Among the promising therapies currently under development are SEFA-1024, DR10624, GC304, and several others, spanning multiple stages of clinical research and showing potential to significantly improve disease management outcomes.
Hypertriglyceridemia Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Hypertriglyceridemia Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertriglyceridemia treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hypertriglyceridemia market.
Download our free sample page report on Hypertriglyceridemia pipeline insights
Hypertriglyceridemia Emerging Drugs
SEFA-1024 – NorthSea Therapeutics
SEFA-1024 is an oral, gut- and liver-targeted semi-synthetic derivative of eicosapentaenoic acid being developed for the treatment of severe hypertriglyceridemia (sHTG)—a condition that significantly elevates the risk of acute pancreatitis and may contribute to cardiovascular complications. Existing treatment options often have limited effectiveness in reducing triglycerides (TG) and non-HDL cholesterol or improving glycemic control, highlighting a substantial unmet clinical need. Supported by promising preclinical results from a human-relevant HTG model, SEFA-1024 demonstrates potential to fill these gaps and is currently undergoing Phase II clinical evaluation for hypertriglyceridemia.
DR10624 – Doer Biologics
DR10624 is a first-in-class, long-acting tri-agonist that simultaneously targets FGF21R, GLP-1R, and the glucagon receptor (GCGR). Developed through Doer Bio’s proprietary MultipleBody platform, it is engineered to provide balanced activity for effective metabolic disease management. Preclinical studies have demonstrated that DR10624 can significantly reduce body weight, lower triglyceride levels, normalize lipid profiles, and enhance liver function. The candidate is currently being evaluated in Phase II clinical trials for the treatment of severe hypertriglyceridemia.
Hypertriglyceridemia Companies
Approximately 18 or more major companies are currently engaged in developing therapies for hypertriglyceridemia, with NorthSea Therapeutics being one of the leading players, having its drug candidates in the most advanced Phase II stage of development.
DelveInsight’s report covers around 75+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Hypertriglyceridemia Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Hypertriglyceridemia Therapies and Key Companies: Hypertriglyceridemia Clinical Trials and advancements
Hypertriglyceridemia Pipeline Therapeutic Assessment
• Hypertriglyceridemia Assessment by Product Type
• Hypertriglyceridemia By Stage
• Hypertriglyceridemia Assessment by Route of Administration
• Hypertriglyceridemia Assessment by Molecule Type
Download Hypertriglyceridemia Sample report to know in detail about the Hypertriglyceridemia treatment market @ Hypertriglyceridemia Therapeutic Assessment
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
